ChloroquineV1, Main, Exploration, bibRecord, 000936

Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome

Identifieur interne : 000936 ( Main/Exploration ); précédent : 000935; suivant : 000937

Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome

Auteurs : J. Mofors ; M. Holmqvist ; L. Westermark ; A. Björk ; M. Kvarnström ; H. Forsblad-D'Elia ; S. Magnusson Bucher ; P. Eriksson ; E. Theander ; T. Mandl ; M. Wahren-Herlenius ; G. Nordmark

Source :

Journal of Internal Medicine [ 0954-6820 ] ; 2019.

RBID : PMC:6851863

Abstract

AbstractBackground

To assess the risk of incident cardiovascular disease in patients with primary Sjögren's syndrome, overall and stratified by Ro/SSA and La/SSB autoantibody status.

Methods

A cohort of patients with primary Sjögren's syndrome in Sweden (n = 960) and matched controls from the general population (n = 9035) were included, and data extracted from the National Patient Register to identify events of myocardial infarction, cerebral infarction and venous thromboembolism. Hazard ratios were estimated using cox proportional hazard regressions.

Results

During a median follow‐up of 9.5 years, the overall hazard ratio (HR) was 1.6 (95% CI 1.2–2.1) for myocardial infarction, 1.2 (95% CI 0.9–1.7) for cerebral infarction and 2.1 (95% CI 1.6–2.9) for venous thromboembolism. Patients positive for both Ro/SSA and La/SSB autoantibodies had a substantially higher risk of cerebral infarction (HR 1.7, 95% CI 1.0–2.9) and venous thromboembolism (HR 3.1, 95% CI 1.9–4.8) than the general population. These risks were not significantly increased in Ro/SSA‐ and La/SSB‐negative patients. Among autoantibody‐positive patients, the highest HR of cerebral infarction was seen after ≥10 years disease duration (HR 2.8, 95% CI 1.4–5.4), while the HR for venous thromboembolism was highest 0–5 years after disease diagnosis (HR 4.7, 95% CI 2.3–9.3) and remained high throughout disease duration.

Conclusions

Primary Sjögren's syndrome is associated with a markedly increased risk of cardiovascular disease and the presence of Ro/SSA and La/SSB autoantibodies identify the subgroup of patients carrying the highest risk. These findings suggest that monitoring and prevention of cardiovascular disease in this patient group should be considered.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851863

DOI: 10.1111/joim.12941
PubMed: 31127862
PubMed Central: 6851863

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Concomitant Ro/<styled-content style="fixed-case" toggle="no">SSA</styled-content>
 and La/<styled-content style="fixed-case" toggle="no">SSB</styled-content>
 antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome</title>
<author><name sortKey="Mofors, J" sort="Mofors, J" uniqKey="Mofors J" first="J." last="Mofors">J. Mofors</name>
<affiliation><nlm:aff id="joim12941-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Holmqvist, M" sort="Holmqvist, M" uniqKey="Holmqvist M" first="M." last="Holmqvist">M. Holmqvist</name>
<affiliation><nlm:aff id="joim12941-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Westermark, L" sort="Westermark, L" uniqKey="Westermark L" first="L." last="Westermark">L. Westermark</name>
<affiliation><nlm:aff id="joim12941-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bjork, A" sort="Bjork, A" uniqKey="Bjork A" first="A." last="Björk">A. Björk</name>
<affiliation><nlm:aff id="joim12941-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kvarnstrom, M" sort="Kvarnstrom, M" uniqKey="Kvarnstrom M" first="M." last="Kvarnström">M. Kvarnström</name>
<affiliation><nlm:aff id="joim12941-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Forsblad Elia, H" sort="Forsblad Elia, H" uniqKey="Forsblad Elia H" first="H." last="Forsblad-D'Elia">H. Forsblad-D'Elia</name>
<affiliation><nlm:aff id="joim12941-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Magnusson Bucher, S" sort="Magnusson Bucher, S" uniqKey="Magnusson Bucher S" first="S." last="Magnusson Bucher">S. Magnusson Bucher</name>
<affiliation><nlm:aff id="joim12941-aff-0005"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Eriksson, P" sort="Eriksson, P" uniqKey="Eriksson P" first="P." last="Eriksson">P. Eriksson</name>
<affiliation><nlm:aff id="joim12941-aff-0006"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Theander, E" sort="Theander, E" uniqKey="Theander E" first="E." last="Theander">E. Theander</name>
<affiliation><nlm:aff id="joim12941-aff-0007"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mandl, T" sort="Mandl, T" uniqKey="Mandl T" first="T." last="Mandl">T. Mandl</name>
<affiliation><nlm:aff id="joim12941-aff-0007"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wahren Erlenius, M" sort="Wahren Erlenius, M" uniqKey="Wahren Erlenius M" first="M." last="Wahren-Herlenius">M. Wahren-Herlenius</name>
<affiliation><nlm:aff id="joim12941-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nordmark, G" sort="Nordmark, G" uniqKey="Nordmark G" first="G." last="Nordmark">G. Nordmark</name>
<affiliation><nlm:aff id="joim12941-aff-0003"></nlm:aff>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">31127862</idno>
<idno type="pmc">6851863</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851863</idno>
<idno type="RBID">PMC:6851863</idno>
<idno type="doi">10.1111/joim.12941</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000680</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000680</idno>
<idno type="wicri:Area/Pmc/Curation">000680</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000680</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000873</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000873</idno>
<idno type="wicri:Area/Ncbi/Merge">000650</idno>
<idno type="wicri:Area/Ncbi/Curation">000650</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000650</idno>
<idno type="wicri:Area/Main/Merge">000936</idno>
<idno type="wicri:Area/Main/Curation">000936</idno>
<idno type="wicri:Area/Main/Exploration">000936</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Concomitant Ro/<styled-content style="fixed-case" toggle="no">SSA</styled-content>
 and La/<styled-content style="fixed-case" toggle="no">SSB</styled-content>
 antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome</title>
<author><name sortKey="Mofors, J" sort="Mofors, J" uniqKey="Mofors J" first="J." last="Mofors">J. Mofors</name>
<affiliation><nlm:aff id="joim12941-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Holmqvist, M" sort="Holmqvist, M" uniqKey="Holmqvist M" first="M." last="Holmqvist">M. Holmqvist</name>
<affiliation><nlm:aff id="joim12941-aff-0002"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Westermark, L" sort="Westermark, L" uniqKey="Westermark L" first="L." last="Westermark">L. Westermark</name>
<affiliation><nlm:aff id="joim12941-aff-0003"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Bjork, A" sort="Bjork, A" uniqKey="Bjork A" first="A." last="Björk">A. Björk</name>
<affiliation><nlm:aff id="joim12941-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Kvarnstrom, M" sort="Kvarnstrom, M" uniqKey="Kvarnstrom M" first="M." last="Kvarnström">M. Kvarnström</name>
<affiliation><nlm:aff id="joim12941-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Forsblad Elia, H" sort="Forsblad Elia, H" uniqKey="Forsblad Elia H" first="H." last="Forsblad-D'Elia">H. Forsblad-D'Elia</name>
<affiliation><nlm:aff id="joim12941-aff-0004"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Magnusson Bucher, S" sort="Magnusson Bucher, S" uniqKey="Magnusson Bucher S" first="S." last="Magnusson Bucher">S. Magnusson Bucher</name>
<affiliation><nlm:aff id="joim12941-aff-0005"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Eriksson, P" sort="Eriksson, P" uniqKey="Eriksson P" first="P." last="Eriksson">P. Eriksson</name>
<affiliation><nlm:aff id="joim12941-aff-0006"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Theander, E" sort="Theander, E" uniqKey="Theander E" first="E." last="Theander">E. Theander</name>
<affiliation><nlm:aff id="joim12941-aff-0007"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Mandl, T" sort="Mandl, T" uniqKey="Mandl T" first="T." last="Mandl">T. Mandl</name>
<affiliation><nlm:aff id="joim12941-aff-0007"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Wahren Erlenius, M" sort="Wahren Erlenius, M" uniqKey="Wahren Erlenius M" first="M." last="Wahren-Herlenius">M. Wahren-Herlenius</name>
<affiliation><nlm:aff id="joim12941-aff-0001"></nlm:aff>
</affiliation>
</author>
<author><name sortKey="Nordmark, G" sort="Nordmark, G" uniqKey="Nordmark G" first="G." last="Nordmark">G. Nordmark</name>
<affiliation><nlm:aff id="joim12941-aff-0003"></nlm:aff>
</affiliation>
</author>
</analytic>
<series><title level="j">Journal of Internal Medicine</title>
<idno type="ISSN">0954-6820</idno>
<idno type="eISSN">1365-2796</idno>
<imprint><date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><title>Abstract</title>
<sec id="joim12941-sec-0001"><title>Background</title>
<p>To assess the risk of incident cardiovascular disease in patients with primary Sjögren's syndrome, overall and stratified by Ro/<styled-content style="fixed-case" toggle="no">SSA</styled-content>
 and La/<styled-content style="fixed-case" toggle="no">SSB</styled-content>
 autoantibody status.</p>
</sec>
<sec id="joim12941-sec-0002"><title>Methods</title>
<p>A cohort of patients with primary Sjögren's syndrome in Sweden (<italic>n</italic>
 = 960) and matched controls from the general population (<italic>n</italic>
 = 9035) were included, and data extracted from the National Patient Register to identify events of myocardial infarction, cerebral infarction and venous thromboembolism. Hazard ratios were estimated using cox proportional hazard regressions.</p>
</sec>
<sec id="joim12941-sec-0003"><title>Results</title>
<p>During a median follow‐up of 9.5 years, the overall hazard ratio (<styled-content style="fixed-case" toggle="no">HR</styled-content>
) was 1.6 (95% <styled-content style="fixed-case" toggle="no">CI</styled-content>
 1.2–2.1) for myocardial infarction, 1.2 (95% <styled-content style="fixed-case" toggle="no">CI</styled-content>
 0.9–1.7) for cerebral infarction and 2.1 (95% <styled-content style="fixed-case" toggle="no">CI</styled-content>
 1.6–2.9) for venous thromboembolism. Patients positive for both Ro/<styled-content style="fixed-case" toggle="no">SSA</styled-content>
 and La/<styled-content style="fixed-case" toggle="no">SSB</styled-content>
 autoantibodies had a substantially higher risk of cerebral infarction (<styled-content style="fixed-case" toggle="no">HR</styled-content>
 1.7, 95% <styled-content style="fixed-case" toggle="no">CI</styled-content>
 1.0–2.9) and venous thromboembolism (<styled-content style="fixed-case" toggle="no">HR</styled-content>
 3.1, 95% <styled-content style="fixed-case" toggle="no">CI</styled-content>
 1.9–4.8) than the general population. These risks were not significantly increased in Ro/<styled-content style="fixed-case" toggle="no">SSA</styled-content>
‐ and La/<styled-content style="fixed-case" toggle="no">SSB</styled-content>
‐negative patients. Among autoantibody‐positive patients, the highest <styled-content style="fixed-case" toggle="no">HR</styled-content>
 of cerebral infarction was seen after ≥10 years disease duration (<styled-content style="fixed-case" toggle="no">HR</styled-content>
 2.8, 95% <styled-content style="fixed-case" toggle="no">CI</styled-content>
 1.4–5.4), while the <styled-content style="fixed-case" toggle="no">HR</styled-content>
 for venous thromboembolism was highest 0–5 years after disease diagnosis (<styled-content style="fixed-case" toggle="no">HR</styled-content>
 4.7, 95% <styled-content style="fixed-case" toggle="no">CI</styled-content>
 2.3–9.3) and remained high throughout disease duration.</p>
</sec>
<sec id="joim12941-sec-0004"><title>Conclusions</title>
<p>Primary Sjögren's syndrome is associated with a markedly increased risk of cardiovascular disease and the presence of Ro/<styled-content style="fixed-case" toggle="no">SSA</styled-content>
 and La/<styled-content style="fixed-case" toggle="no">SSB</styled-content>
 autoantibodies identify the subgroup of patients carrying the highest risk. These findings suggest that monitoring and prevention of cardiovascular disease in this patient group should be considered.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Bjork, A" sort="Bjork, A" uniqKey="Bjork A" first="A." last="Björk">A. Björk</name>
<name sortKey="Eriksson, P" sort="Eriksson, P" uniqKey="Eriksson P" first="P." last="Eriksson">P. Eriksson</name>
<name sortKey="Forsblad Elia, H" sort="Forsblad Elia, H" uniqKey="Forsblad Elia H" first="H." last="Forsblad-D'Elia">H. Forsblad-D'Elia</name>
<name sortKey="Holmqvist, M" sort="Holmqvist, M" uniqKey="Holmqvist M" first="M." last="Holmqvist">M. Holmqvist</name>
<name sortKey="Kvarnstrom, M" sort="Kvarnstrom, M" uniqKey="Kvarnstrom M" first="M." last="Kvarnström">M. Kvarnström</name>
<name sortKey="Magnusson Bucher, S" sort="Magnusson Bucher, S" uniqKey="Magnusson Bucher S" first="S." last="Magnusson Bucher">S. Magnusson Bucher</name>
<name sortKey="Mandl, T" sort="Mandl, T" uniqKey="Mandl T" first="T." last="Mandl">T. Mandl</name>
<name sortKey="Mofors, J" sort="Mofors, J" uniqKey="Mofors J" first="J." last="Mofors">J. Mofors</name>
<name sortKey="Nordmark, G" sort="Nordmark, G" uniqKey="Nordmark G" first="G." last="Nordmark">G. Nordmark</name>
<name sortKey="Theander, E" sort="Theander, E" uniqKey="Theander E" first="E." last="Theander">E. Theander</name>
<name sortKey="Wahren Erlenius, M" sort="Wahren Erlenius, M" uniqKey="Wahren Erlenius M" first="M." last="Wahren-Herlenius">M. Wahren-Herlenius</name>
<name sortKey="Westermark, L" sort="Westermark, L" uniqKey="Westermark L" first="L." last="Westermark">L. Westermark</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000936 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000936 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:6851863
   |texte=   Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:31127862" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

Serveur d'exploration Chloroquine

Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome

Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sjögren's syndrome

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.